Department of Dermatology and Venereology, Erasmus MC, Rotterdam, The Netherlands.
J Eur Acad Dermatol Venereol. 2012 Oct;26(10):1197-202. doi: 10.1111/j.1468-3083.2012.04449.x. Epub 2012 Feb 4.
The skin-blanching assay is used for the determination and bioequivalence of dermatologic glucocorticoids (GCs). The exact mechanism of the production of blanching is not fully understood, but it is considered that local vasoconstriction of the skin microvasculature and the consequent blood-flow reduction cause this phenomenon. Several factors influence skin blanching, including drug concentration, duration of application, nature of vehicle, occlusion, posture and location. The intensity of vasoconstriction can be measured in several ways: visual or quantitative methods, such as reflectance spectroscopy, thermography, laser Doppler velocimetry and chromametry. In literature, contradicting results in the correlation of the skin-blanching assay with different tests to determine GC sensitivity have been reported, limiting its clinical usefulness.
皮肤发白试验用于测定和生物等效性的皮肤科糖皮质激素(GCs)。确切的发病机制的生产发白并不完全清楚,但它被认为是局部皮肤血管收缩和随后的血流减少造成这种现象。有几个因素影响皮肤发白,包括药物浓度,应用时间,性质的车辆,闭塞,姿势和位置。血管收缩的强度可以用几种方法来测量:视觉或定量的方法,如反射光谱,热成像,激光多普勒测速和比色法。在文献中,在皮肤发白试验与不同的测试结果相矛盾的相关性已经被报道,以确定 GC 敏感性,限制了其临床应用。